MedTrace Logo

GCF Galectin-3 and Interleukin-1beta Levels in Periodontitis.

NCT05449093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-07-08

No results posted yet for this study

Summary

This study aims to evaluate gingival crevicular fluid Galectin-3 and Interleukin-1beta levels in different grades (B and C) of stage 3 periodontitis, concurrently, and also to investigate their discriminative efficiencies in periodontal diseases. A total of 80 systemically healthy and non-smoker individuals, 20 stage 3 grade C periodontitis 20 stage 3 grade B periodontitis, 20 gingivitis and 20 periodontally healthy were enrolled. Clinical periodontal parameters were recorded and GCF Galectin-3 and interleukin-1 beta total amounts were measured by ELISA. Receiver operating characteristics curve was used for estimating the area under the curve.

Conditions

  • Periodontitis
  • Periodontal Inflammation

Interventions

OTHER

Periodontal clinical measurements and gingival crevicular fluid sampling

Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe. Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device.

Sponsors & Collaborators

  • Aydin Adnan Menderes University

    lead OTHER

Principal Investigators

  • Beral Afacan · Aydin Adnan Menderes University

  • Gülnur Emingil · İzmir Ege University

  • Harika Atmaca İlhan · Manisa Celal Bayar University

  • Timur Köse · İzmir Ege University

Eligibility

Min Age
25 Years
Max Age
52 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-21
Primary Completion
2019-08-23
Completion
2019-09-02

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05449093 on ClinicalTrials.gov